Taking aim at Ewing's sarcoma: is KIT a target and will imatinib work?
Druker
Brian J
BJ
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001549:Benzamides; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology; D017321:Clinical Trials, Phase I as Topic; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D010879:Piperazines / Q000494:pharmacology* / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D019009:Proto-Oncogene Proteins c-kit / Q000187:drug effects*; D011743:Pyrimidines / Q000494:pharmacology* / Q000627:therapeutic use; D012512:Sarcoma, Ewing / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D019009:Proto-Oncogene Proteins c-kit